VERA THERAPEUTICS INC (VERA) Stock Analyst Earnings Estimates
NASDAQ:VERA - Nasdaq - US92337R1014 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A 404.96% | N/A 149.48% | N/A 69.72% | N/A 35.63% | N/A 26.11% | N/A 19.58% | ||||||
| EBITDA YoY % growth | -11.08M | -47.81M -331.50% | -34.22M 28.43% | N/A -126.53% | N/A -27.63% | -167.065M -68.85% | N/A -33.67% | N/A 16.90% | N/A 46.76% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -11.59M | -48.06M -314.67% | -34.4M 28.42% | -90.9M -164.24% | -102.012M -12.22% | -167.17M -63.87% | N/A -39.44% | N/A 1.65% | N/A 8.32% | N/A 114.27% | N/A 763.68% | N/A 81.60% | N/A 40.96% | N/A 30.83% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -13.71 | -3.35 75.57% | -2.31 31.04% | -2.75 -19.05% | N/A -21.46% | N/A -4.52% | N/A 31.96% | N/A 243.42% | N/A 71.71% | N/A 28.86% | N/A 26.18% | N/A 14.69% |
All data in USD
| Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.84 -35.18% | -0.86 -1.00% | -0.90 -25.02% | -0.94 -15.64% | -4.09 -388.03% |
| Revenue Q2Q % growth | |||||
| EBITDA Q2Q % growth | -56.1M -50.33% | -54.06M -8.66% | -57.12M -17.03% | N/A | N/A |
| EBIT Q2Q % growth | -57.127M -52.98% | -59.392M -19.26% | -64.514M -31.89% | -66.32M -15.96% | -73.44M -28.56% |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2025 Q2Q % growth | -0.81 -44.64% | -0.75 | -0.06 | -8.04% |
| Q4 2024 Q2Q % growth | -0.72 -20.00% | -0.85 | 0.13 | 15.67% |
| Q3 2024 Q2Q % growth | -0.85 -88.89% | -0.67 | -0.18 | -26.69% |
| Q2 2024 Q2Q % growth | -0.62 -34.78% | -0.57 | -0.05 | -8.54% |
| Q1 2024 Q2Q % growth | -0.56 30.00% | -0.54 | -0.02 | -3.59% |
| Q4 2023 Q2Q % growth | -0.60 49.15% | -0.52 | -0.08 | -15.84% |
| Q3 2023 Q2Q % growth | -0.45 50.55% | -0.54 | 0.09 | 17.28% |
| Q2 2023 Q2Q % growth | -0.46 16.36% | -0.71 | 0.25 | 34.95% |
| Q1 2023 Q2Q % growth | -0.80 -12.68% | -0.62 | -0.18 | -29.85% |
| Q4 2022 Q2Q % growth | -1.18 -49.37% | -0.92 | -0.26 | -28.07% |
| Q3 2022 Q2Q % growth | -0.91 -152.78% | -0.74 | -0.17 | -23.62% |
| Q2 2022 Q2Q % growth | -0.55 -66.67% | -0.73 | 0.18 | 24.93% |
| Q1 2022 Q2Q % growth | -0.71 94.19% | -0.68 | -0.03 | -3.89% |
| Q4 2021 Q2Q % growth | -0.79 | -0.47 | -0.32 | -66.56% |
| Q3 2021 Q2Q % growth | -0.36 | -0.61 | 0.25 | 40.68% |
| Q2 2021 Q2Q % growth | -0.33 | -0.40 | 0.07 | 17.04% |
| Q1 2021 Q2Q % growth | -12.23 | -1.98 | -10.25 | -516.46% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | -1.86% | -6.43% | 0% | -4.11% |
| Revenue | N/A | N/A | N/A | N/A |